SUSTIVA
LOE ApproachingNDAORALTABLET
Approved
Feb 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
SUSTIVA by Bristol Myers Squibb is [see clinical pharmacology ]. Approved for human immunodeficiency virus type 1 (hiv-1) infection, combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection. First approved in 2002.
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUSTIVA is an oral small-molecule tablet approved by the FDA in 2002 for an unknown indication under Bristol Myers Squibb sponsorship. The specific mechanism of action and therapeutic indications are not provided in available data. This product represents a mature legacy asset in the NDA portfolio.
$25KPart D
LOE ApproachingDeclining
Minimal commercial footprint with only 26 Part D claims in 2023 suggests a small, legacy brand team focused on retention rather than growth.
Mechanism of Action
[see Clinical Pharmacology ].
Worked on SUSTIVA at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.